Informations générales (source: ClinicalTrials.gov)
Management of Symptomatic Advanced Pancreatic Adenocarcinoma: "Urgence Pancreas" - A Prospective A.R.CA.D Cohort Study
Interventional
N/A
GERCOR - Multidisciplinary Oncology Cooperative Group (Voir sur ClinicalTrials)
novembre 2016
octobre 2020
29 juin 2024
This study assessed the feasibility and effects of an early integrative supportive care
program in patient with Advanced pancreatic adenocarcinoma (aPDAC).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Beaujon | Pascal HAMMEL, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Cochin | Romain CORIAT, MD | Contact (sur clinicalTrials) | |||
| GH PARIS SITE SAINT JOSEPH | Eric RAYMOND, MD | Contact (sur clinicalTrials) | |||
| INSTITUT MUTUALISTE MONTSOURIS | Christophe LOUVET, MD | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CH Layne - Mont de Marsan - France | Jérôme DAUBA, MD | Contact (sur clinicalTrials) | |||
| CHU Tours - Hôpital Trousseau - Tours - France | Thierry LECOMTE, MD | Contact (sur clinicalTrials) | |||
| Hopitaux du Léman - Thonon les Bains - France | Ahmed BEDJAOUI, MD | Contact (sur clinicalTrials) | |||
| Institut Sainte Catherine - Avignon - France | Philippe DEBOURDEAU, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Léon Bérard - Lyon - France | Christelle De la FOUCHARDIERE, MD | Contact (sur clinicalTrials) | |||
| Hôpital Henri Mondor - Créteil - France | Benoît ROUSSEAU, MD | Contact (sur clinicalTrials) | |||
| Hôpital Pitié Salpêtrière - Paris - France | Jean Baptiste BACHET, MD | Contact (sur clinicalTrials) | |||
| Institut Hospitalier Franco-Britannique - Levallois Perret - France | Aimery DE GRAMONT, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria - STEP 1:
1. Pathologically confirmed or highly suspected aPDAC defined as a pancreatic mass on
imaging, suspected distant metastases, no features suggestive of a neuroendocrine
tumor, and/or clinico-biological abnormalities compatible with the diagnosis of
aPDAC,
2. Age ≥ 18 years,
3. Patients with ECOG PS ≥ 2 and clinico-biological features precluding initial
therapeutic clinical trial and/or treatment with FOLFIRINOX or gemcitabine +
nab-paclitaxel,
4. No prior history of cancer, except: in situ breast, cervix cancer, or basal cell
carcinoma and/or complete remission for more than 3 years from another cancer.
5. Registration in France with the French National Health Care System (CMU included)
6. Patient able to comply with study protocol requirements in the view of the
investigator,
7. Before patient registration, written informed consent must be obtained according to
ICH/GCP and national/local regulations,
8. Patients requiring at least two components of the integrative care program (pain
management, nutritional management, pathological assessment or imaging, and
endoscopy/stent).
Exclusion Criteria - STEP 1 :
1. Any medical, psychological, familial, sociological, or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial,
2. Patient protected by law,
3. Pregnant or breast feeding women
1. Pathologically confirmed or highly suspected aPDAC defined as a pancreatic mass on
imaging, suspected distant metastases, no features suggestive of a neuroendocrine
tumor, and/or clinico-biological abnormalities compatible with the diagnosis of
aPDAC,
2. Age ≥ 18 years,
3. Patients with ECOG PS ≥ 2 and clinico-biological features precluding initial
therapeutic clinical trial and/or treatment with FOLFIRINOX or gemcitabine +
nab-paclitaxel,
4. No prior history of cancer, except: in situ breast, cervix cancer, or basal cell
carcinoma and/or complete remission for more than 3 years from another cancer.
5. Registration in France with the French National Health Care System (CMU included)
6. Patient able to comply with study protocol requirements in the view of the
investigator,
7. Before patient registration, written informed consent must be obtained according to
ICH/GCP and national/local regulations,
8. Patients requiring at least two components of the integrative care program (pain
management, nutritional management, pathological assessment or imaging, and
endoscopy/stent).
Exclusion Criteria - STEP 1 :
1. Any medical, psychological, familial, sociological, or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial,
2. Patient protected by law,
3. Pregnant or breast feeding women